Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia

@article{OBrien2003EffectsOI,
  title={Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia},
  author={Stephen G. O'Brien and Patricia Meinhardt and Elisabeth Bond and Joachim Beck and B K Peng and Catherine Dutreix and Guenther H. Mehring and Slavica Milosavljev and Chris Huber and Renaud Capdeville and Thomas Fischer},
  journal={British Journal of Cancer},
  year={2003},
  volume={89},
  pages={1855 - 1859}
}
The inhibition by imatinib of the cytochrome P450 3A4 isoenzyme may reduce the CYP3A4-mediated metabolic clearance of clinically important coadministered drugs. The main purpose of this study was to evaluate the effect of the coadministration of imatinib on the pharmacokinetics of simvastatin, a probe CYP3A4 substrate. In total, 20 patients with chronic myeloid leukaemia received an oral dose of 40 mg of simvastatin on study day 1. On study days 2–7, each patient received 400 mg of imatinib… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 50 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 32 references

Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative

  • E Buchdunger, J Zimmerman, +4 authors NB Lydon
  • Cancer Res 56:
  • 1996
Highly Influential
4 Excerpts

Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia

  • PA Todd, KL Goa
  • Drugs 40:
  • 1990
Highly Influential
2 Excerpts

Similar Papers

Loading similar papers…